Prognostic Significance of Tumor Markers in Colorectal Cancer Patients: DNA Index, S-Phase Fraction, p53 Expression, and Ki-67 Index

Journal of Gastrointestinal Surgery

Volumn 1, Issue 3, 1997, Pages 266-273

  Chen, Ya Ting ^a   Henk, Mary Jo ^b   Carney, Kathy Jean ^c   Wong, W Douglas ^b   Rothenberger, David A ^b   Zheng, Tongzhang ^a   Feygin, Marina ^c   Madoff, Robert D ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c Dianon Systems   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0001718636     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1091-255X(97)80119-9     Document Type: Article

References (46)

1. National Institutes of Health Consensus Conference. Adjuvant therapy for patients with colon and rectal cancer: Summary of NIH Consensus Conference. JAMA 1990;264:1444-1450.
2. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-358.
3. Gerdes J, Kemke H, Baisch H, et al. Cell cycle analysis of cell proliferation associated human nuclear antigen defined by the monoclonal antibody K-67. J Immunol 1984;133:1710-1715.
4. Banks L, Matlashewski G, Crawford L. Isolation of human p53 specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem 1986;159:529-534.
5. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
6. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959;22:719-748.
7. SPSS Advanced Statistics 6.1. Chicago: SPSS, 1994.
8. Jass JR, Love SB, Northover JM. A new prognostic classification of rectal cancer. Lancet 1987;1:1303-1306.
9. Jen J, Kim H, Piantadosi S, et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994; 331:213-221.
10. Chapuis PH, Dent OF, Fisher R, et al. A multivariate analysis of clinical and pathological variables in prognosis after resection of large bowel cancer. Br J Surg 1985;72:698-702.
11. Isbister WH, Fraser J. Survival following resection for colorectal cancer: A New Zealand national study. Dis Colon Rectum 1985;28:725-727.
12. Griffin MR, Bergstralh EJ, Coffey RJ, et al. Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987;60:2318-2324.
13. Fielding LP, Phillips RKS, Fry JS, et al. Prediction of outcome after curative resection for large bowel cancer. Lancet 1986; 2:904-907.
14. Kune GA, Kune S, Field B, et al. Survival in patients with large-bowel cancer. Dis Colon Rectum 1990;33:938-946.
15. Bravo R, Frank R, Blundell PA, et al. Cyclin/PCNA is the auxiliary protein of DNA-polymerase delta. Nature 1987;326: 515-517.
16. Hall PA. Cell proliferation. J Pathol 1991;165:349-354.
17. Diebold J, Dopfer K, Lai M, et al. Comparison of different monoclonal antibodies for the immunohistochemical assessment of cell proliferation in routine colorectal biopsy specimens. Scand J Gastroenterol 1994;29:47-53.
18. Al-Sheneber IF, Shibata HR, Sampalis J, et al. Prognostic significance of proliferating cell nuclear antigen expression in colorectal cancer. Cancer 1993;71:1945-1949.
19. Gerdes J, Li L, Schluter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by the monoclonal antibody Ki-67. AmJ Pathol 1991;138:867-875.
20. Cattoretti G, Becker MHG, Key G, et al. Monoclonal antibodies against recombinant parts of the Ki-67 antigen (mibl and mib3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 1992;168:357-363.
21. Kubota Y, Petras RE, Easley KA, et al. Ki-67 determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992;70:2602-2609.
22. Porschen R, Kriegel A, Langen C, et al. Assessment of proliferative activity in carcinomas of the human alimentary tract by Ki-67 immunostaining. IntJ Cancer 1991;47:686-691.
23. Witzig TE, Loprinzi CL, Gonchoroff NJ, et al. DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stage B2 and C colorectal adenocarcinoma. Cancer 1991;68:879-888.
24. Dean PA, Vernava AM III. Flow cytometric analysis of DNA content in colorectal carcinoma. Dis Colon Rectum 1992;35: 95-102.
25. Kokal W, Sheibani K, Terz J, et al. Tumor DNA content in the prognosis of colorectal carcinoma. JAMA 1986;255:3123-3127.
26. Scott NA, Rainwater LM, Weigand HS, et al. The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma. Dis Colon Rectum 1987;30:513-520.
27. Jones DJ, Moore M, Schofield PF. Prognostic significance of DNA ploidy in colorectal cancer: A prospective flow cytometric study. Br J Surg 1988;75:28-33.
28. Quirke P, Dixon MF, Clayden A, et al. Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J Pathol 1987;151:285-291.
29. Fischer ER, Siderits RH, Sass R, et al. Value of assessment of ploidy in rectal cancers. Arch Pathol Lab Med 1989;113:525-528.
30. Hood DL, Petras RE, Edinger M, et al. Deoxyribonucleic acid ploidy and cell cycle analysis of colorectal carcinoma by flow cytometry. AmJ Clin Pathol 1990;93:615-620.
31. Crissman JD, Zarbo RJ, Ma CK, et al. Histopathologic parameters and DNA analysis in colorectal adenocarcinomas. Pathol Annu 1989;24(part 2):103-147.
32. Emdin SO, Stenling R, Roos G. Prognostic value of DNA content in colorectal carcinoma: A flow cytometric study with some methodologic aspects. Cancer 1987;60:1282-1287.
33. Quirke P, Dixon MF, Clayden A, et al. Prognostic significance of DNA aneuploidy and cell proliferation in rectal adenocarcinomas. J Pathol 1987;151:285-291.
34. Schutte B, Reynders MMJ, Wiggers T, et al. Retrospective analysis of the prognostic significance of DNA content and proliferative activity in large bowel carcinoma. Cancer Res 1987;47:5494-5496.
35. Scott NA, Wiegand HS, Moertel CG, et al. Colorectal cancer: Dukes stage, tumor site, pre-operative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg 1987;122:1375-1379.
36. Scott NA, Rainwater LM, Wiegand HS, et al. The relative prognostic value of flow cytometric DNA analysis and conventional clinicopathologic criteria in patients with operable rectal carcinoma. Dis Colon Rectum 1987;30:513-520.
37. Scott NA, Grande JP, Weiland LH, et al. Flow cytometric DNA patterns from colorectal cancers - how reproducible are they? Mayo Clin Proc 1987;62:331-337.
38. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992;70:523-526.
39. Levine AJ. The p53 tumor supressor gene and product. Cancer Surv 1992;12:59-80.
40. Finlay CA, Hinds PW, Tan TH, et al. Activating mutations for transformation by p53 produce a gene project that forms an hsc700-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-539.
41. Wynford-Thomas D. p53 in tumour pathology: Can we trust immunocytochemistry? J Pathol 1992;166:329-330.
42. Goh H-S, Chan C-S, Khine K, et al. p53 and behaviour of colorectal cancer. Lancet 1994;344:233-234.
43. Bell SM, Scott N, Cross D, et al. Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer. Gastroenterology 1993;104:57-64.
44. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994;106:42-48.
45. Campo E, Miquel R, Jares P, et al. Prognostic significance of the loss of heterozygosity of Nm23-H1 and p53 genes in human colorectal carcinomas. Cancer 1994;73:2913-2921.
46. Baas IO, Mulder JR, Johan G, et al. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.